세계의 비대성 심근병증(HCM) 치료제 시장 보고서(2025년)

Hypertrophic cardiomyopathy (HCM) therapeutics refer to the treatment of a condition characterized by the abnormal thickening (hypertrophy) of the heart muscle, leading to impaired blood-pumping efficiency. The goal of hypertrophic cardiomyopathy therapeutics is to alleviate symptoms and prevent sudden cardiac death, particularly in high-risk patients.

The primary drug types used in hypertrophic cardiomyopathy therapeutics include antiarrhythmic agents, anticoagulants, beta-adrenergic blocking agents, calcium channel blockers, and others. Antiarrhythmic agents are medications designed to address abnormal heart rhythms or arrhythmias. Additionally, various devices, such as defibrillators, pacemakers, and others, are employed in hospitals and clinics as part of the therapeutic approach to managing hypertrophic cardiomyopathy.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hypertrophic cardiomyopathy (HCM) therapeutics market research report is one of a series of new reports from The Business Research Company that provides hypertrophic cardiomyopathy (HCM) therapeutics market statistics, including hypertrophic cardiomyopathy (HCM) therapeutics industry global market size, regional shares, competitors with hypertrophic cardiomyopathy (HCM) therapeutics market share, detailed hypertrophic cardiomyopathy (HCM) therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hypertrophic cardiomyopathy (HCM) therapeutics industry. This hypertrophic cardiomyopathy (HCM) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown marginally in recent years. It will grow from $1.34 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 1.5%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding.

The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to genetic research and personalized medicine, emerging therapeutic modalities, collaborative research initiatives, patient-centric healthcare models, local health initiatives. Major trends in the forecast period include advancements in targeted therapies, personalized medicine and genetic testing, drug pipeline expansion, collaborations and partnerships, patient-centric approaches.

The forecast of 3.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of cardiac myosin inhibitors and implantable defibrillators sourced from Switzerland and Germany, thereby delaying life-saving interventions and elevating cardiology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the hypertrophic cardiomyopathy (HCM) therapeutics market is anticipated to be propelled by the increasing prevalence of cardiovascular diseases (CVD). CVD refers to conditions affecting the heart or blood vessels, encompassing irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block, necessitating prolonged monitoring. Therapeutics for hypertrophic cardiomyopathy primarily aim to alleviate symptoms and prevent sudden cardiac death in high-risk patients. According to the October 2022 report from the Center for Disease Control and Prevention (CDCP), one person succumbs to cardiovascular disease in the United States every 36 seconds, contributing to nearly 836,546 deaths in the country alone in 2021. Thus, the rising incidence of CVD serves as a driving force for the hypertrophic cardiomyopathy (HCM) therapeutics market.

The surge in clinical trials is expected to further drive the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Clinical trials, systematic investigations assessing the safety, efficacy, and potential side effects of new medical treatments, drugs, or interventions, play a crucial role in evaluating the effectiveness of Hypertrophic Cardiomyopathy (HCM) Therapeutics. As of May 2023, there were 452,604 registered clinical trials globally on ClinicalTrials.gov, as reported by Xtalks, indicating a notable increase from the 365,000 trials recorded in early 2021. Therefore, the escalation in clinical trials is a significant factor propelling the hypertrophic cardiomyopathy (HCM) therapeutics market.

A key trend gaining traction in the hypertrophic cardiomyopathy (HCM) therapeutics market is product innovation. Major players in the cardiomyopathy therapeutics sector are actively involved in developing innovative products to enhance their market position. In April 2022, Bristol Myers Squibb, a U.S.-based biopharmaceutical company, introduced Camzyos (mavacamten), an oral small-molecule cardiac myosin inhibitor for treating hypertrophic cardiomyopathy (HCM) and heart diastolic dysfunction diseases. FDA-approved for adults with symptomatic class II-III obstructive hypertrophic cardiomyopathy, Camzyos is the first and only allosteric and reversible inhibitor of cardiac myosin, addressing the underlying pathophysiology of obstructive HCM by controlling the number of myosin heads entering power-generating states on actin.

Key players in the hypertrophic cardiomyopathy (HCM) therapeutics market are concentrating on innovations, such as novel gene-targeting therapies, to offer patients advanced treatment options that enhance heart function and alleviate the symptoms of both obstructive and non-obstructive HCM. Mavacamten (Camzyos) is a drug specifically designed to treat symptomatic obstructive hypertrophic cardiomyopathy (HOCM) by reducing excessive contractions of the heart muscle, thereby improving heart function and easing symptoms. For example, in May 2022, Bristol Myers Squibb (BMS), a biopharmaceutical company based in the U.S., launched mavacamten (Camzyos), which is available in capsule strengths of 2.5 mg, 5 mg, 10 mg, and 15 mg for the treatment of adults with symptomatic New York Heart Association (NYHA) class 2-3 obstructive hypertrophic cardiomyopathy (HOCM) to enhance functional capacity and reduce symptoms.

In November 2023, Merck Sharp & Dohme, a U.S.-based pharmaceutical company, acquired Caraway Therapeutics, Inc. for an undisclosed amount. This acquisition enables Merck to utilize its industry-leading research and development capabilities to advance innovative therapies for genetically defined neurodegenerative and rare diseases, with the goal of developing disease-modifying treatments that can significantly impact disease progression. Caraway Therapeutics is a U.S.-based biopharmaceutical firm focused on developing small-molecule therapeutics for rare and neurodegenerative diseases.

Major companies operating in the hypertrophic cardiomyopathy (HCM) therapeutics market include Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Advanz Pharma Corp., Lupin Limited, Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories

North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypertrophic cardiomyopathy (HCM) therapeutics market consists of revenues earned by entities by provide progressive disease management, physical therapy (PT), and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic cardiomyopathy (HCM) therapeutics market also consists of sales of disopyramide, wearable heart monitoring devices, and cardiac rhythm management (CRM) devices which are used in providing hypertrophic cardiomyopathy (HCM) therapeutics services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypertrophic cardiomyopathy (hcm) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypertrophic cardiomyopathy (hcm) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hypertrophic cardiomyopathy (hcm) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Antiarrhythmic Agents; Anticoagulants; Beta Adrenergic Blocking Agents; Calcium Channel Blockers; Other Drug Types
• 2) By Device Type: Defibrillators; Pacemakers; Other Device Types
• 3) By End User: Hospitals; Clinics
• Subsegments:
• 1) By Antiarrhythmic Agents: Class I Agents; Class II Agents; Class III Agents; Class IV Agents
• 2) By Anticoagulants: Vitamin K Antagonists; Direct Oral Anticoagulants (DOACs); Low Molecular Weight Heparins (LMWH)
• 3) By Beta Adrenergic Blocking Agents: Non-Selective Beta Blockers; Selective Beta Blockers
• 4) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
• 5) By Other Drug Types: Myosin Inhibitors; Antimetabolites; Other Novel Agents
• Companies Mentioned: Merck & Co. Inc.; Pfizer Inc.; Sanofi SA; Teva Pharmaceutical Industries Ltd.; Novartis AG; AstraZeneca plc; Gilead Sciences Inc.; Bayer AG; Correvio Pharma Corp.; Advanz Pharma Corp.; Lupin Limited; Boston Scientific Corporation; Bristol-Myers Squibb Company; Johnson & Johnson; Medtronic plc; Cardiome Pharma Corp.; Cytokinetics Inc.; Daiichi Sankyo Company Limited; GlaxoSmithKline plc.; HUYA Bioscience International LLC; Ionis Pharmaceuticals Inc.; Kowa Company Ltd.; Luitpold Pharmaceuticals Inc.; Menarini Group; Mitsubishi Tanabe Pharma Corporation; Nippon Shinyaku Co. Ltd.; Otsuka Holdings Co. Ltd.; Servier Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Characteristics

3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends And Strategies

4. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Growth Rate Analysis
• 5.4. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Total Addressable Market (TAM)

6. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segmentation

• 6.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiarrhythmic Agents
• Anticoagulants
• Beta Adrenergic Blocking Agents
• Calcium Channel Blockers
• Other Drug Types
• 6.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Defibrillators
• Pacemakers
• Other Device Types
• 6.3. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• 6.4. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Sub-Segmentation Of Antiarrhythmic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Class I Agents
• Class II Agents
• Class III Agents
• Class IV Agents
• 6.5. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Sub-Segmentation Of Anticoagulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin K Antagonists
• Direct Oral Anticoagulants (DOACs)
• Low Molecular Weight Heparins (LMWH)
• 6.6. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Sub-Segmentation Of Beta Adrenergic Blocking Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Selective Beta Blockers
• Selective Beta Blockers
• 6.7. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dihydropyridines
• Non-Dihydropyridines
• 6.8. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Myosin Inhibitors
• Antimetabolites
• Other Novel Agents

7. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Regional And Country Analysis

• 7.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 8.1. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 9.1. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 9.2. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 10.1. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 11.1. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 11.2. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 12.1. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 13.1. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 14.1. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 14.2. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 15.1. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 15.2. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 16.1. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 17.1. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 18.1. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 19.1. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 20.1. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 21.1. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 21.2. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 22.1. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 23.1. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 23.2. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 24.1. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 24.2. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 25.1. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 25.2. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 26.1. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 26.2. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 27.1. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 28.1. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 28.2. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

• 29.1. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
• 29.2. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Landscape
• 30.2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Gilead Sciences Inc.
• 31.3. Bayer AG
• 31.4. Correvio Pharma Corp.
• 31.5. Advanz Pharma Corp.
• 31.6. Lupin Limited
• 31.7. Boston Scientific Corporation
• 31.8. Bristol-Myers Squibb Company
• 31.9. Johnson & Johnson
• 31.10. Medtronic plc
• 31.11. Cardiome Pharma Corp.
• 31.12. Cytokinetics Inc.
• 31.13. Daiichi Sankyo Company Limited
• 31.14. GlaxoSmithKline plc.
• 31.15. HUYA Bioscience International LLC

32. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

34. Recent Developments In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

35. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer